VivoSim Labs, Inc. Capital Expenditures Incurred but Not yet Paid
VivoSim Labs, Inc. (VIVS) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 12-month period ending 2024-03-31, per its 10-K filed 2024-05-31.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-05-31
- VivoSim Labs, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- VivoSim Labs, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $64.00K.
- VivoSim Labs, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|
| 2024-03-31 | $0.00 10-K · filed 2024-05-31 |
| 2023-03-31 | $64.00K 10-K · filed 2024-05-31 |
| 2022-03-31 | $0.00 10-K · filed 2023-07-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |